GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
Abstract Soft tissue sarcoma (STS) is a predominantly fatal rare malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies. Its therapeutic relevance in STS is unknown. We analyzed the prognostic impact of GSK-3β gene and protein e...
Guardado en:
Autores principales: | S. Verbeke, R. Perret, V. Chaire, E. Richard, V. Velasco, F. Giles, L. Cavalcante, A. Italiano |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cbb98c95e2e745d88a7d6d2402a0a230 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MEDICAL TREATMENT IN EWING SARCOMA
por: Roberto Luksch
Publicado: (2021) -
GSK-3 protein and the heart: friend or foe?
por: B. Huisamen, et al.
Publicado: (2017) -
CAN SERUM KL-6 LEVEL BE USED AS A MARKER IN LUNG METASTASIS OF BONE SARCOMAS?
por: Turan BAYHAN, et al.
Publicado: (2021) -
PRIMARY EWING'S SARCOMA OF SPHENOID BONE EXTENDING TO BRAINSTEM; AN ORDINARY TUMOUR AT AN EXTRAORDINARY LOCATION AND INVOLVEMENT
por: Seda ŞAHİN, et al.
Publicado: (2021) -
Amniotic fluid exerts a neurotrophic influence on fetal neurodevelopment via the ERK/GSK-3 pathway
por: Jang,Yongwoo, et al.
Publicado: (2015)